TYK Medicines Inc
02410
Company Profile
Business description
TYK Medicines Inc is a clinical-stage biopharmaceutical company. The company is engaged in drug discovery research and development. The company and its subsidiaries are principally engaged in the research, development, and commercialization of pharmaceutical products. The company has built a pipeline with10 drug candidates, including Core Product TY-9591, five clinical stage products, and four preclinical stage or early clinical development stage.
Contact
No.277 Longlan Road
8th Floor, Building T2
China Eastern Binjiang Center
Xuhui District
Shanghai
CHNT: +86 2161676766
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
173
Stocks News & Analysis
stocks
ASX healthcare share remains undervalued ahead of earnings
Margin recovery remains the key driver for this ASX healthcare share.
stocks
Alphabet earnings: Strong AI monetization continues to spearhead results
We maintain our fair value estimate for wide-moat Alphabet.
stocks
AMD: We’re pleased with Anthropic Partnership ahead of advancing AI event
We’re encouraged that AMD will count Anthropic as a third leading AI customer, in addition to OpenAI and Meta.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,941.50 | 32.70 | -0.36% |
| CAC 40 | 8,372.28 | 0.00 | 0.00% |
| DAX 40 | 25,099.00 | 335.88 | 1.36% |
| Dow JONES (US) | 51,947.25 | 235.60 | 0.46% |
| FTSE 100 | 10,736.23 | 97.06 | 0.91% |
| HKSE | 24,963.23 | 247.58 | -0.98% |
| NASDAQ | 24,975.82 | 161.87 | -0.64% |
| Nikkei 225 | 64,611.15 | 1,811.45 | -2.73% |
| NZX 50 Index | 13,772.29 | 23.02 | -0.17% |
| S&P 500 | 7,411.98 | 3.68 | 0.05% |
| S&P/ASX 200 | 8,772.30 | 23.40 | -0.27% |
| SSE Composite Index | 3,814.20 | 62.58 | -1.61% |